| Generic name | Pralatrexate |
| Pronunciation | PRAL-a-trek-sate |
| Brand name(s), other common name(s) | Folotyn® |
| Drug type | Antimetabolite |
| How the drug is given | Intravenously (IV) |
Indications and Usage
Pralatrexate is FDA approved to treat people who have relapsed or refractory peripheral T-cell lymphoma. It is being studied to treat people who have other forms of lymphoma including diffuse large B-cell lymphoma.
Side effects needing medical attention
Mouth sores; tiredness (fatigue); nausea; myelosuppression; infections.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.